This paradox complicates IFN-γ replacement therapy in COPD–PA: in the COPD-dominant phenotype, elevated IFN-γ contraindicates supplementation, whereas in the PA-dominant phenotype, IFN-γ therapy may be feasible but likely within a narrow therapeutic window. This evidence concerns the gene IFNG and chronic obstructive pulmonary disease.